REG - Genflow Biosciences - Administrative Approval of Grant & 2026 Priorities

Genflow BiosciencesAnnouncement

28/01/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260128:nRSb5966Qa&default-theme=true

RNS Number : 5966Q  Genflow Biosciences PLC  28 January 2026

 

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO
CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION
(EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN
UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS
ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS
CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

Genflow Biosciences Plc

 

Administrative Approval of €4 Million Funding Support from Wallonia Region
for GF-100; and 2026 Development Priorities

 

Genflow Biosciences Plc (LSE: GENF) (OTCQB: GENFF) ("Genflow" or the
"Company"), a European-based biotechnology company focused on the development
of gene therapies for age-related diseases, announces the administrative
approval of the previously announced award of approximately €4 million in
non-dilutive financial support from the Wallonia Region of Belgium, following
the assenting signature of Minister Adrien Dolimont.

 

The funding, once received, will support the continued development of the
Company's lead gene therapy candidate, GF-1002, for the treatment of Metabolic
Dysfunction-Associated Steatohepatitis ("MASH"). The original RNS announcing
the award can be found here
(https://www.londonstockexchange.com/news-article/GENF/genflow-secures-non-dilutive-financial-support/16725188)
.

 

Disbursement of the first instalment is expected no later than May 2026. The
support package spans a three-year development programme and is aligned with
Genflow's existing roadmap. All project-related expenses incurred during 2025
will be eligible under the terms of the programme.

 

Development Priorities for 2026

In 2026 Genflow's strategy emphasises pipeline discipline and capital
efficiency, prioritising programmes with the strongest data, the clearest
paths to value creation, and the highest potential for partner engagement.
Central to this approach is the pursuit of early-stage collaboration
agreements designed to secure non-dilutive funding, provide external
validation of the platform, and support continued development.

 

With multiple anticipated data readouts, an expanding partner dialogue, and a
maturing intellectual property position, Genflow believes it is well
positioned to enter its next phase of development while maintaining a focus on
scientific rigour, operational execution, and long-term shareholder value
creation.

 

Dog Aging (GF-1004)

The ongoing GF-1004 dog aging study, which commenced in March 2025, is being
conducted as a blinded clinical trial designed to assess potential benefits
related to sarcopenia, healthspan, and lifespan-associated biomarkers.

 

An initial efficacy readout is expected in the first quarter of 2026. Dogs
enrolled in the study are being monitored over a 180-day period, with a second
efficacy assessment planned at the six-month timepoint. Results from this
later evaluation are expected in June-July 2026 and are intended to assess
durability and longer-term effects.

 

Glaucoma Programme

The Company's glaucoma programme will prioritise delivery optimisation and
execution readiness. Genflow is advancing discussions with a leading lipid
nanoparticle (LNP) partner to support delivery innovation and is progressing
the selection of a full-service contract research organisation (CRO) to manage
RNA-based formulation activities through preclinical execution.

 

Additional Programmes

Across the broader pipeline, Genflow continues to advance its sarcopenia
programme in line with established development plans. In parallel, the
ExoFastTrack initiative continues to generate data intended to support and
accelerate multiple programmes across the portfolio.

 

Dr. Eric Leire, CEO of Genflow, commented: "The administrative approval of
this funding reinforces our ability to execute against our 2026 development
priorities with discipline and focus. It strengthens our capacity to advance
GF-1002 while maintaining a selective, data-driven approach across the broader
pipeline. As we enter the coming year, our emphasis remains on programmes with
clear execution paths, strong scientific rationale, and meaningful
opportunities for partnership and non-dilutive value creation."

 

Contacts

 Genflow Biosciences  Harbor Access
 Dr Eric Leire, CEO   Jonathan Paterson, Investor Relations
 +32-477-495-881      +1 475 477 9401
                      Jonathan.Paterson@Harbor-access.com

 

About Genflow Biosciences

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a
biotechnology company headquartered in the UK with R&D facilities in
Belgium, is pioneering gene therapies for age-related diseases, with the goal
of promoting longer and healthier lives while mitigating the financial,
emotional, and social impacts of a fast-growing aging global population.
Genflow's lead compound, GF-1002, works through the delivery of a centenarian
variant of the SIRT6 gene which has yielded promising preclinical results.
Genflow's 12-month proof-of-concept clinical trial evaluating their
SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other
programs, include a clinical trial that will explore the potential benefits of
GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis),
the most prevalent chronic liver disease for which there is no effective
treatments. Please visit www.genflowbio.com (http://www.genflowbio.com)   and
follow the Company on LinkedIn
(https://www.linkedin.com/company/genflow-biosciences/?viewAsMember=true) and
X (https://x.com/genflowbio) .

 

DISCLAIMER

The contents of this announcement have been prepared by, and are the sole
responsibility of, the Company.

This announcement may contain forward-looking statements. The forward-looking
statements include, but are not limited to, statements regarding the Company's
or the Directors' expectations, hopes, beliefs, intentions or strategies
regarding the future. In addition, any statement that refers to projections,
forecasts or other characterisations of future events or circumstances,
including any underlying assumptions, is a forward-looking statement. The
words "anticipate", "believe", "continue", "could", "estimate", "expect",
"intend", "may", "might", "plan", "possible", "potential", "predict",
"project", "seek", "should", "would" and similar expressions, or in each case
their negatives, may identify forward-looking statements, but the absence of
these words does not mean that a statement is not forward-looking.

Forward-looking statements include all matters that are not historical facts.
Forward-looking statements are based on the current expectations and
assumptions regarding the Company, the business, the economy and other future
conditions. Because forward-looking statements relate to the future, by their
nature, they are subject to inherent uncertainties, risks and changes in
circumstances that are difficult to predict. Forward-looking statements are
not guarantees of future performance and the Company's actual financial
condition, actual results of operations and financial performance, and the
development of the industries in which it operates or will operate, may differ
materially from those made in or suggested by the forward-looking statements
contained in this announcement. In addition, even if the Company's financial
condition, results of operations and the development of the industries in
which it operates or will operate, are consistent with the forward-looking
statements contained in this announcement, those results or developments may
not be indicative of financial condition, results of operations or
developments in subsequent periods. Important factors that could cause actual
results to differ materially from those in the forward-looking statements
include regional, national or global, political, economic, social, business,
technological, competitive, market and regulatory conditions.

Any forward-looking statement contained in this announcement applies only as
of the date of this announcement and is expressly qualified in its entirety by
these cautionary statements. Factors or events that could cause the Company's
actual plans or results to differ may emerge from time to time, and it is not
possible for the Company to predict all of them. The Company expressly
disclaims any obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained in this announcement to
reflect any change in its expectations or any change in events, conditions or
circumstances on which any forward-looking statement contained in this
announcement is based, unless required to do so by applicable law, the
Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and
Transparency Rules of the FCA or the UK Market Abuse Regulation.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEALFXALFKEFA



            Copyright 2019 Regulatory News Service, all rights reserved